EEDQ
Based on 1 Customer Validation
EEDQ is a carboxylate activator and irreversible antagonist of 5HT2c receptors. EEDQ reduces [3H]β-CIT binding to the dopamine transporter (DAT) in rat caudate-putamen (CPu) homogenates (IC50 = 78.3 μM). EEDQ inhibits contralateral rotation behavior.
For research use only. We do not sell to patients.
- Purity: 99.97%
- CAS No.: 16357-59-8
- Formula: C14H17NO3
- Molecular Weight:247.29
-
Storage:Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 6 months , -20°C, 1 month
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Biological Activity
-
Chemical Information
-
Solvent & Solubility
- Purity & Documentation
- References
-
Help & FAQs
All 5-HT Receptor Isoforms
More
Biological Activity
EEDQ (1 mM; 30 min) has no effect on glycogen phosphorylase activity or cell viability of hepatocytes[1].
EEDQ (10-300 μM) concentration-dependently decreases [3H]β-CIT binding to dopamine transporters (DAT) in rat caudate-putamen (CPu) homogenates (IC50 = 78.3 μM)[3].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
EEDQ (7.5 mg/kg; i.p.) does not disrupt NPA-induced stereotyped sniffing and locomotor activity in 11-day-old and 17-day-old Sprague-Dawley rat pups[5].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
Chemical Information
-
CAS No. 16357-59-8
-
Appearance Solid
-
Molecular Weight 247.29
-
Formula C14H17NO3
-
Color White to off-white
-
SMILES
O=C(N1C(OCC)C=CC2=C1C=CC=C2)OCC
-
Synonyms
EEDQ
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month
Solvent & Solubility
DMSO : 100 mg/mL (404.38 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Select the appropriate dissolution method based on your experimental animal and administration route.
- For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
- To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
- The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: ≥ 5 mg/mL (20.22 mM); Clear solution
This protocol yields a clear solution of ≥ 5 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (50.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)
Solubility: ≥ 5 mg/mL (20.22 mM); Clear solution
This protocol yields a clear solution of ≥ 5 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (50.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.
Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.
Please enter the basic information of animal experiments:
-
-
-
-
Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Please enter your animal formula composition:
-
%DMSO +
Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
-
%+
-
+%Tween-80 + +
-
%Saline +
The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).
Working solution concentration: 0.22 mg/mL
Method for preparing stock solution: mg drug dissolved in μL DMSO. Stock solution concentration: mg/mL.
1. Take μL DMSO stock solution;
2. Add μL .
μL , mix evenly;
3. Then add μL Tween 80, mix evenly;
4. Then add μL
Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
Purity & Documentation
-
Data Sheet (277 KB)
-
SDS (396 KB)
- English - EN (396 KB)
- Français - FR (396 KB)
- Deutsch - DE (396 KB)
- Norwegian - NO (396 KB)
- Español - ES (396 KB)
- Swedish - SV (396 KB)
- Italian - IT (396 KB)
- Korean - KR (396 KB)
- Portuguese - PT (396 KB)
-
Handling Instructions (2659 KB)
References
[2]. Ni YG, et al. Irreversible antagonism of 5HT2c receptors by N-ethoxycarbonyl-2-ethoxy-1,2-dihydroquinoline (EEDQ). Proc Natl Acad Sci U S A. 1997 Mar 18;94(6):2715-8. [Content Brief]
[3]. Tarazi FI, et al. Alkylation of rat dopamine transporters and blockade of dopamine uptake by EEDQ. Neuropharmacology. 2000 Aug 23;39(11):2133-8. [Content Brief]
[4]. Goodale DB, et al. Selective protection from the inhibition by EEDQ of D1 and D2 dopamine agonist-induced rotational behavior in mice. Pharmacol Biochem Behav. 1988 Jun;30(2):457-62. [Content Brief]
[5]. Mestlin M, et al. Ontogenetic differences in the effects of EEDQ on dopamine-mediated behaviors. Pharmacol Biochem Behav. 1993 Aug;45(4):797-802. [Content Brief]
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 4.0438 mL | 20.2192 mL | 40.4384 mL | 101.0959 mL |
| 5 mM | 0.8088 mL | 4.0438 mL | 8.0877 mL | 20.2192 mL | |
| 10 mM | 0.4044 mL | 2.0219 mL | 4.0438 mL | 10.1096 mL | |
| 15 mM | 0.2696 mL | 1.3479 mL | 2.6959 mL | 6.7397 mL | |
| 20 mM | 0.2022 mL | 1.0110 mL | 2.0219 mL | 5.0548 mL | |
| 25 mM | 0.1618 mL | 0.8088 mL | 1.6175 mL | 4.0438 mL | |
| 30 mM | 0.1348 mL | 0.6740 mL | 1.3479 mL | 3.3699 mL | |
| 40 mM | 0.1011 mL | 0.5055 mL | 1.0110 mL | 2.5274 mL | |
| 50 mM | 0.0809 mL | 0.4044 mL | 0.8088 mL | 2.0219 mL | |
| 60 mM | 0.0674 mL | 0.3370 mL | 0.6740 mL | 1.6849 mL | |
| 80 mM | 0.0505 mL | 0.2527 mL | 0.5055 mL | 1.2637 mL | |
| 100 mM | 0.0404 mL | 0.2022 mL | 0.4044 mL | 1.0110 mL |
EEDQ Related Classifications
HY-Y1191 Related Classifications
Powered by Bioz